Organogenesis Holdings, Inc. Class A ORGO

The latest update on Organogenesis Holdings centers on a cut to the assessed fair value and price target from US$3.00 to US$2.00, which marks a reduction of around one third. Analysts framing this shift with Hold ratings describe a mix of potential opportunity and clear near term challenges. This reflects a more cautious but still balanced view of risk and reward. As you read on, you will see how this revised price target fits into the evolving narrative around guidance, reimbursement...

In August 2026, Organogenesis Holdings Inc. reported second-quarter revenue of US$43.76 million and a net loss of US$96.27 million, alongside sharply reduced full-year 2026 revenue guidance and a US$75.00 million at-the-market equity offering. These results highlighted a very large year-over-year revenue contraction and a significantly wider loss per share, even as new Affinity clinical data added support to the company’s chronic wound care portfolio. We’ll now examine how this steep revenue...

Moby summary of Organogenesis Holdings Inc.'s Q2 2026 earnings call

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Results Summary: Net revenue of $42.8 million for the second quarter of

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th. Management will host a conference call at

PDUFA Target Action Date Set for April 24, 2027CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing determination and accepted for review the Company's Biologics License Application (BLA) for ReNu®, a cryopreserved, amniotic susp

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Organogenesis Holdings Inc. (NASDAQ:ORGO) is one of the best pharmaceutical stocks on our list. TheFly reported on May 8 that BTIG downgraded ORGO to Neutral from Buy in a post–first-quarter update, with the price target withdrawn. The revised view reflects […]

Over the last 7 days, the market has remained flat, but it is up 25% over the past year with earnings forecast to grow by 17% annually. In such a climate, identifying stocks with strong financial foundations can be key to finding value and growth opportunities. Penny stocks, although an older term, remain relevant as they often represent smaller or newer companies that may offer significant potential when backed by solid fundamentals.

Over the last 7 days, the United States market has remained flat, yet it has shown a robust 25% rise over the past 12 months with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially undervalued and have insider buying can be an effective strategy for investors looking to capitalize on growth opportunities.

Moby summary of Organogenesis Holdings Inc.'s Q1 2026 earnings call

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Summary: Net revenue of $36.3 million for the first quarter of 20

If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA painCANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a rolling Biologics License Application (BLA) submission to the Food and Drug Adm